Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
WALD
$1.48
$0.01
Waldencast Acquisition Corp. a skin care company, provides advanced skin care treatments. Its products are designed to help minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage primarily available through dermatologists, plastic surgeons, medical spas, and other skin care professionals. Its portfolio includes Obagi Medical that provides transformational skin care products formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines, and wrinkles and to protect and enhance skin tone and texture; and Obagi Clinical that offers skin care products designed to prevent the early signs of skin aging. The company was founded in 1988 and is based in White Plains, New York.
Next Earnings
2026-01-11
Beta
-0.471
Average Volume
99111
Market Cap
167290572
Last Dividend
0
CIK
0001840199
ISIN
JE00BPG99318
CUSIP
G9503X103
CEO
Michel Brousset
Sector
Technology
Industry
Software - Application
Full Time Employees
335
IPO Date
2021-05-12
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD | NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Waldencast plc ("Waldencast" or the "Company") (NASDAQ: WALD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. | PRNewsWire | 2026-01-08 10:00:00 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD | NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Waldencast plc (“Waldencast” or the “Company”) (NASDAQ: WALD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. | GlobeNewsWire | 2026-01-06 12:04:00 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD | NEW YORK, Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Waldencast plc ("Waldencast" or the "Company") (NASDAQ: WALD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. | PRNewsWire | 2026-01-01 10:00:00 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD | NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Waldencast plc (“Waldencast” or the “Company”) (NASDAQ: WALD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. | GlobeNewsWire | 2025-12-30 15:52:00 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Waldencast plc - WALD | NEW YORK , Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Waldencast plc ("Waldencast" or the "Company") (NASDAQ: WALD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. | PRNewsWire | 2025-12-11 10:00:00 |
| Novo Nordisk, Waldencast And Other Big Stocks Moving Lower In Monday's Pre-Market Session | U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday. | Benzinga | 2025-11-24 08:08:04 |
| Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting | Obagi® saypha® ChIQ™ data selected as a top 10 cosmetic oral abstract presentation Obagi® saypha® ChIQ™ data selected as a top 10 cosmetic oral abstract presentation | GlobeNewsWire | 2025-11-16 01:02:00 |
| Waldencast plc strengthens balance sheet position with the announcement of a trademark sale for Japan and refinancing of its credit facilities | NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that it had sold its rights to the “Obagi” trademark in Japan to Rohto Pharmaceutical Co., Ltd. (“Rohto”) for USD $82.5 million. | GlobeNewsWire | 2025-11-14 17:05:00 |
| Waldencast plc Provides Information Regarding Upcoming Earnings Release Dates | First Half Fiscal 2025 Results and Q3 2025 Financial Results Expected to be Reported on November 24, 2025 First Half Fiscal 2025 Results and Q3 2025 Financial Results Expected to be Reported on November 24, 2025 | GlobeNewsWire | 2025-11-12 07:33:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 6-K | 2025-12-19 | 2025-12-19 | View Filing |
| EFFECT | 2025-12-18 | 2025-12-19 | View Filing |
| 424B3 | 2025-12-18 | 2025-12-18 | View Filing |
| F-3 | 2025-12-04 | 2025-12-04 | View Filing |
| 6-K | 2025-11-14 | 2025-11-14 | View Filing |
| 6-K | 2025-09-10 | 2025-09-10 | View Filing |
| SC 13G | 2025-09-04 | 2025-09-04 | View Filing |
| SC 13G/A | 2025-08-19 | 2025-08-19 | View Filing |
| 6-K | 2025-08-18 | 2025-08-18 | View Filing |
| 6-K | 2025-07-23 | 2025-07-23 | View Filing |
| SC 13G | 2025-05-19 | 2025-05-19 | View Filing |
| 6-K | 2025-05-14 | 2025-05-14 | View Filing |
| 6-K | 2025-05-13 | 2025-05-13 | View Filing |
| 20-F | 2025-03-20 | 2025-03-20 | View Filing |
| 6-K | 2025-03-19 | 2025-03-19 | View Filing |
| 6-K | 2025-03-18 | 2025-03-18 | View Filing |
| SC 13D/A | 2025-01-30 | 2025-01-30 | View Filing |
| 6-K | 2024-11-21 | 2024-11-21 | View Filing |
| 6-K | 2024-11-20 | 2024-11-20 | View Filing |
| 20-F/A | 2024-11-20 | 2024-11-20 | View Filing |
| 6-K | 2024-11-13 | 2024-11-13 | View Filing |
| 6-K | 2024-10-30 | 2024-10-30 | View Filing |
| 6-K | 2024-10-07 | 2024-10-07 | View Filing |
| 6-K | 2024-08-28 | 2024-08-28 | View Filing |
| 6-K | 2024-08-27 | 2024-08-27 | View Filing |
| 6-K | 2024-08-27 | 2024-08-27 | View Filing |
| 6-K | 2024-08-21 | 2024-08-21 | View Filing |
| 424B3 | 2024-07-08 | 2024-07-08 | View Filing |
| EFFECT | 2024-07-08 | 2024-07-08 | View Filing |
| 6-K | 2024-06-27 | 2024-06-27 | View Filing |
| F-3 | 2024-06-26 | 2024-06-26 | View Filing |
| 6-K | 2024-05-21 | 2024-05-21 | View Filing |
| 6-K | 2024-05-13 | 2024-05-13 | View Filing |
| 6-K | 2024-04-30 | 2024-04-30 | View Filing |
| 20-F | 2024-04-30 | 2024-04-30 | View Filing |
| 6-K | 2024-03-25 | 2024-03-25 | View Filing |
| 6-K | 2024-03-21 | 2024-03-20 | View Filing |
| 6-K | 2024-03-21 | 2024-03-20 | View Filing |
| 6-K | 2024-02-26 | 2024-02-26 | View Filing |
| SC 13D/A | 2024-02-09 | 2024-02-09 | View Filing |
| SC 13G | 2024-02-01 | 2024-02-01 | View Filing |
| 6-K | 2024-01-31 | 2024-01-31 | View Filing |
| SC 13G/A | 2024-01-31 | 2024-01-31 | View Filing |
| 6-K | 2024-01-16 | 2024-01-16 | View Filing |
| 20-F | 2024-01-16 | 2024-01-16 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Bollinger Bands Strategy | 607.20% | 1 | 101 | 0.03 | 0.36 | 539.06 |
| Larry Williams PercentR Strategy | 506.19% | 1 | 287 | 0.03 | 0.27 | 438.05 |
| Keltner Channel Strategy | 434.48% | 1 | 261 | 0.03 | 0.26 | 366.34 |
| xxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxxx |
| xxxxxxxxx | xxxxxx% | x | xxxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxx | xxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | x | xxxx | xxxxx |
| xxxxxxxxxxxxx | x% | x | xxxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxxx |